Simulations Plus, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended November 30, 2018; Provides Revenue Guidance for the Year 2019
January 09, 2019 at 09:05 pm
Share
Simulations Plus, Inc. announced unaudited consolidated earnings results for the first quarter ended November 30, 2018. For the quarter, the company reported revenue of $7,535,903 against $7,068,782 for the same period a year ago. Income from operations was $2,086,745 against $2,563,843 for the same period a year ago. Income before provision for income taxes was $2,021,618 against $2,517,004 for the same period a year ago. Net income was $1,535,947 against $1,716,005 for the same period a year ago. Basic earnings per share were $0.09 against $0.10 for the same period a year ago.
The company outlook for full year 2019 revenue growth of 10% to 15%.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Simulations Plus, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended November 30, 2018; Provides Revenue Guidance for the Year 2019